MMS22 like, DNA repair proteinGenealiases: C6orf167 · dJ39B17.2
Q-omics provides the consensus-scored MMS22L profile across patient tissues and cancer cell-line models. MMS22L expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MMS22L is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, MMS22L RNA expression shows 21,100 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, HNSC, and LSCC as cancer lineages where MMS22L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MMS22L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MMS22L survival associations across molecular data types. MMS22L RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MMS22L RNA expression–survival associations across cancer types. High MMS22L expression shows unfavorable associations in MESO, KIRP, LIHC, ACC, KICH and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MMS22L RNA expression.
This table summarizes MMS22L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MMS22L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MMS22L shows higher tumor expression in HNSC, BLCA, COAD, KIRC, STAD and KIRP. The HNSC box plot shows higher MMS22L RNA expression in tumor versus normal tissue (log2 FC = +1.279, t-test p < 0.001).
This table shows molecular features associated with MMS22L in patient tissues and cancer cell lines. In patient samples, MMS22L shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MMS22L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
